Atlas Trials

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

Clinical trial NCT04739358 · TERMINATED

Trial details

NCT number
NCT04739358
Sponsor
Criterium, Inc.
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Advanced Non-Small Cell Lung Cancer With MET Mutations
Start date
2022-05-25
Primary completion
2023-06-23
Enrollment
2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.